159 related articles for article (PubMed ID: 1385959)
1. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
Matsunaga A; Handa K; Mori T; Moriyama K; Hidaka K; Yuki M; Sasaki J; Arakawa K
Atherosclerosis; 1992 Jun; 94(2-3):241-8. PubMed ID: 1385959
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
Yamauchi K; Tanahashi Y; Okada M; Tsuzuki J; Sato A; Abe K; Inagaki H; Agetsuma H; Hattori R; Izawa H
Clin Ther; 1995; 17(1):52-9. PubMed ID: 7758061
[TBL] [Abstract][Full Text] [Related]
4. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
5. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
Artery; 1982; 10(4):266-85. PubMed ID: 7181672
[TBL] [Abstract][Full Text] [Related]
6. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
[TBL] [Abstract][Full Text] [Related]
8. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
9. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
10. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
Saku K; Zhang B; Hirata K; Okura Y; Bai H; Liu R; Arakawa K
Eur J Clin Pharmacol; 1993; 44(6):535-9. PubMed ID: 8405008
[TBL] [Abstract][Full Text] [Related]
13. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
Tanaka K; Hayashi K; Shingu T; Kuga Y; Okura Y; Yasunobu Y; Ohtani H; Nomura S; Kurushima H; Saeki M; Kambe M; Kajiyama G
Metabolism; 1997 Apr; 46(4):355-8. PubMed ID: 9109834
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.
Curtis LD; Reckless JP; Winder AF; Betteridge DJ
Postgrad Med J; 1988 Sep; 64(755):672-5. PubMed ID: 3075043
[TBL] [Abstract][Full Text] [Related]
15. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
[TBL] [Abstract][Full Text] [Related]
16. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
17. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia.
Yamamoto K; Fukushima N; Ozaki I; Setoguchi Y; Yanagita T; Sakai T
Artery; 1991; 18(3):133-49. PubMed ID: 2069518
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
Lijnen P; Celis H; Desager JP; Fagard R
J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
[TBL] [Abstract][Full Text] [Related]
19. Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease.
Sano R; Fujino A; Saito T; Takenaka K; Yahata Y; Ogyu A; Toyota T
Tohoku J Exp Med; 1993 Apr; 169(4):299-307. PubMed ID: 8248919
[TBL] [Abstract][Full Text] [Related]
20. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
